- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc stock price live, this page displays NYSE RCUS stock exchange data. View the RCUS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arcus Biosciences Inc real time stock price chart below.
What Is the Arcus Biosciences Inc Stock Price Today?
The Arcus Biosciences Inc stock price today is 9.18.
What Is the Stock Symbol for Arcus Biosciences Inc?
The stock symbol for Arcus Biosciences Inc is ""RCUS.""
What Stock Exchange Does Arcus Biosciences Inc Trade On?
Arcus Biosciences Inc is listed and trades on the NYSE stock exchange.
Is Arcus Biosciences Inc a Good Stock to Buy?
Determining whether Arcus Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RCUS quote. (ISIN: US03969F1093)
What Is the Arcus Biosciences Inc Stock Price Today?
The Arcus Biosciences Inc stock price today is 9.18.
What Is the Stock Symbol for Arcus Biosciences Inc?
The stock symbol for Arcus Biosciences Inc is ""RCUS.""
What Stock Exchange Does Arcus Biosciences Inc Trade On?
Arcus Biosciences Inc is listed and trades on the NYSE stock exchange.
Is Arcus Biosciences Inc a Good Stock to Buy?
Determining whether Arcus Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RCUS quote. (ISIN: US03969F1093)
9.18
-0.38(-3.93%)
Real-time Data·
Fair Value
An estimate of a Arcus Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.10
9.50
52 wk Range
6.50
18.98
RCUS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected today
1/2
Fair Value
An estimate of a Arcus Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.109.50
52 wk Range
6.5018.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RCUS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arcus Biosciences's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
28.18
Upside
+206.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Arcus Biosciences Inc Company Profile
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences Inc SWOT Analysis
Promising Pipeline | Explore Arcus Biosciences' lead candidate casdatifan, showing potential in renal cell carcinoma trials with a 46% objective response rate in combination therapy |
Financial Outlook | Delve into Arcus's financial position, with analysts forecasting further earnings decline but stock potentially undervalued with price targets ranging from $12 to $46 |
Market Positioning | Learn how Arcus's HIF-2alpha inhibitor casdatifan competes against established players, potentially offering improved efficacy in the oncology landscape |
Future Catalysts | Discover key upcoming events for Arcus, including data presentations and trial updates, with analysts assigning a 70% likelihood to positive outcomes |
Arcus Biosciences Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS of -1.14 missed forecast of -1.02; revenue of $28M fell short of $38.61M projection
- Strong cash position of $1B maintained; 2025 expected to be peak year for R&D expenses
- Full-year 2025 revenue guidance of $75-90M reaffirmed despite Q1 miss
- Strategic focus on castadefan development and AstraZeneca collaboration for RCC market
- Stock recovered 1.85% in aftermarket trading following 9.17% drop during regular hours
Last Updated: 06/05/2025, 22:38
Read Full TranscriptCompare RCUS to Peers and Sector
Metrics to compare | RCUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRCUSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −1.1x | −0.5x | |
PEG Ratio | 0.06 | −0.06 | 0.00 | |
Price/Book | 1.9x | 2.3x | 2.6x | |
Price / LTM Sales | 7.2x | 9.9x | 3.3x | |
Upside (Analyst Target) | 172.3% | 302.0% | 42.8% | |
Fair Value Upside | Unlock | 22.7% | 6.5% | Unlock |
Analyst Ratings
11 Buy
2 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 28.18
(+206.99% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-1.14 / -1.02
Revenue / Forecast
28.00M / 38.61M
People Also Watch
FAQ
What Stock Exchange Does Arcus Biosciences Trade On?
Arcus Biosciences is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Arcus Biosciences?
The stock symbol for Arcus Biosciences is "RCUS."
What Is the Arcus Biosciences Market Cap?
As of today, Arcus Biosciences market cap is 974.14M.
What Is Arcus Biosciences's Earnings Per Share (TTM)?
The Arcus Biosciences EPS (TTM) is -4.20.
When Is the Next Arcus Biosciences Earnings Date?
Arcus Biosciences will release its next earnings report on 05 Aug 2025.
From a Technical Analysis Perspective, Is RCUS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Arcus Biosciences Stock Split?
Arcus Biosciences has split 0 times.
How Many Employees Does Arcus Biosciences Have?
Arcus Biosciences has 627 employees.
What is the current trading status of Arcus Biosciences (RCUS)?
As of 06 Aug 2025, Arcus Biosciences (RCUS) is trading at a price of 9.18, with a previous close of 9.55. The stock has fluctuated within a day range of 9.10 to 9.50, while its 52-week range spans from 6.50 to 18.98.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.